<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10901361</article-id><article-id pub-id-type="pmc">2363492</article-id><article-id pub-id-type="pii">6691236</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1236</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ohtsu</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Baba</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sakata</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mitachi</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Horikoshi</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Sugimachi</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Taguchi</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><collab>for the S-1 Cooperative Colorectal Carcinoma Study Group</collab></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Gastrointestinal Oncology/Gastroenterology, National Cancer Center Hospital East, Kashiwa</aff><aff id="aff2"><label>2</label>Department of Gastroenterologic Surgery, National Kyushu Cancer Center, Fukuoka</aff><aff id="aff3"><label>3</label>Department of Gastroenterology, Aomori Prefectural Central Hospital, Aomori</aff><aff id="aff4"><label>4</label>Department of Gastroenterology and Medical Oncology, Sendai Kosei Hospital, Miyagi</aff><aff id="aff5"><label>5</label>Chemotherapy Cancer Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo</aff><aff id="aff6"><label>6</label>Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka</aff><aff id="aff7"><label>7</label>Japan Society for Cancer Chemotherapy, Osaka, Japan</aff><pub-date pub-type="epub"><day>15</day><month>06</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>07</month><year>2000</year></pub-date><volume>83</volume><issue>2</issue><fpage>141</fpage><lpage>145</lpage><history><date date-type="received"><day>16</day><month>07</month><year>1999</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD). Sixty-three patients with measurable metastatic colorectal carcinoma were enrolled into the study. None of the patients had received prior chemotherapy except for adjuvant setting. S-1 was administered orally twice daily at a standard dose of 80 mg m<sup>&#x02013;2</sup>day<sup>&#x02013;1</sup>for 28 days followed by a 14-day rest. This agent is continued until disease progression, unaccepted toxicity, or patient refusal. Twenty-two (35&#x00025;) of the 62 eligible patients achieved PR with a 95&#x00025; confidence interval of 25&#x02013;48&#x00025;. Five of the 10 patients with a history of adjuvant chemotherapy achieved partial remission. The median survival time was 12 months. Major adverse reactions included myelosuppressive and gastrointestinal toxicities, though their incidence of grade 3 or 4 being 13&#x00025; in neutropenia and less than 10&#x00025; in the others. None of the 53 patients treated as outpatients required hospitalization due to adverse reactions: These results suggest that S-1 achieves similar responses to those of infusional 5-FU plus leucovorin and shows the potential of another biochemical modulation with easily manageable toxicity. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>metastatic colorectal carcinoma</kwd><kwd>tegafur</kwd><kwd>CDHP</kwd><kwd>S-1</kwd></kwd-group></article-meta></front></article>


